公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial | Piccart-Gebhart M.; Holmes E.; Baselga J.; De Azambuja E.; Dueck A.C.; Viale G.; Zujewski J.A.; Goldhirsch A.; Armour A.; Pritchard K.I.; McCullough A.E.; Dolci S.; McFadden E.; Holmes A.P.; Tonghua L.; Eidtmann H.; Dinh P.; Di Cosimo S.; Harbeck N.; Tjulandin S.; Im Y.-H.; CHIUN-SHENG HUANG ; Diéras V.; Hillman D.W.; Wolff A.C.; Jackisch C.; Lang I.; Untch M.; Smith I.; Boyle F.; Xu B.; Gomez H.; Suter T.; Gelber R.D.; Perez E.A. | Journal of Clinical Oncology | 307 | 277 | |
2013 | Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial | Azim H.A.; Agbor-Tarh D.; Bradbury I.; Dinh P.; Baselga J.; Di Cosimo S.; Greger Jr. J.G.; Smith I.; Jackisch C.; Kim S.-B.; Aktas B.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.K.; Dreosti L.; Eidtmann H.; Piccart M.; De Azambuja E. | Journal of Clinical Oncology | 48 | 47 |